查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1961257

甲狀腺癌診斷市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、技術、最終用途、地區和競爭格局分類，2021-2031年

Thyroid Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Technique, By End-use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球甲狀腺癌診斷市場預計將從 2025 年的 27.3 億美元成長到 2031 年的 35.2 億美元，複合年成長率為 4.33%。

該領域涵蓋多種臨床評估方法，旨在識別和表徵甲狀腺惡性腫瘤，包括高解析度成像、細針穿刺切片檢查和分子基因組學檢測。推動該市場成長要素是全球內分泌疾病盛行率的不斷上升，以及為改善治療效果而對早期疾病檢測的迫切需求。日益加重的疾病負擔需要嚴格的篩檢通訊協定，並直接推動了專業診斷技術的應用。根據美國癌症協會 (ACS) 的數據，到 2025 年，美國預計將新增約 44,020 例甲狀腺癌病例，這凸顯了迫切需要精準的診斷設備來有效應對如此龐大的患者群體。

市場概覽
預測期 2027-2031
市場規模：2025年 27.3億美元
市場規模：2031年 35.2億美元
複合年成長率：2026-2031年 4.33%
成長最快的細分市場 乳頭狀癌
最大的市場 北美洲

儘管市場呈現成長態勢，但仍面臨一項重大挑戰：低度甲狀腺結節的過度診斷，這種做法往往導致不必要的手術和過度治療。為此，監管機構修訂了篩檢指南，建議對小型、低風險結節採取更保守的治療方案。這些臨床實踐的改變造成了報銷的不確定性，並減少了輕症病例的診斷程序，阻礙了市場的進一步擴張。

市場促進因素

全球甲狀腺癌發生率的上升是診斷市場的主要驅動力，因此需要製定完善的篩檢通訊協定來應對不斷成長的患者數量。這種成長在年輕人群體中尤為顯著，迫使醫療系統加強診斷能力，以便早期療育。世界衛生組織（WHO）國際癌症研究機構（IARC）於2025年11月發布的題為《青少年和青年甲狀腺癌》的研究報告顯示，2022年全球該年齡層新增甲狀腺癌病例超過23.7萬例。這一成長趨勢也體現在各國統計數據中；例如，英國癌症研究中心在2025年9月報告稱，該地區每年約有4000例新增甲狀腺癌病例，這凸顯了在不同人群中持續開發有效檢測方法的必要性。

同時，分子診斷和基因組分析的整合正在改變臨床工作流程。這有助於解決難以確定性質的甲狀腺結節的診治難題。先進的基因組分類工具使醫生能夠更準確地區分良性和惡性結節，從而減少不必要的診斷性手術，並確保資源的有效利用。精準醫療的轉型體現在專業檢測產品的顯著成長。 Verasite在2025年2月發布的2024年第四季及全年財報中宣布，其Affima基因組檢測的銷量成長了12%，2024年全年檢測量超過6萬次。如此高的普及率表明，分子檢測正迅速成為標準診療流程，並透過高附加價值診斷程序推動市場收入成長。

市場挑戰

甲狀腺癌診斷市場面臨的一大障礙是臨床診療模式的轉變，即減少對低度甲狀腺結節的過度診斷。過去，發現小型、低風險結節通常會促使醫生進行積極的診斷評估，但目前的臨床實踐越來越傾向於對小型病灶採取積極後續觀察而非即時進行細針穿刺切片檢查或分子檢測。這種保守治療的轉變直接降低了診斷干預的頻率，減少了檢測總數，並限制了診斷機構的收入來源。

由於醫療系統實施更嚴格的報銷標準以消除低風險病例相關的不必要成本，檢測數量的下降給市場帶來了挑戰。根據加拿大癌症協會估計，到2025年，加拿大預計將有約6900人被診斷出患有甲狀腺癌。雖然這種發病率擴大了潛在患者群體，但臨床指南選擇性的提高意味著接受全面診斷的甲狀腺結節患者數量將會減少。因此，由於醫療機構將這些高精度診斷工具的使用限制在高風險惡性腫瘤，而非用於對輕微結節進行常規篩檢，企業面臨著獲取這些工具管道受限的困境。

市場趨勢

將人工智慧 (AI) 和機器學習技術應用於診斷影像，從根本上改變了甲狀腺癌的檢測方式，提高了超音波檢查的準確性，並最佳化了臨床操作。人工智慧演算法擴大被用於評估超音波觀察，與傳統的視覺分析相比，它能更準確地區分良性和惡性結節。這項技術進步正在消除不同檢查者之間的操作差異，並顯著提高臨床效率。例如，在 RamSoft 於 2025 年 9 月發布的新聞稿「RamSoft 與 Koios Medical 合作」中，他們指出，將 Koios DS 人工智慧軟體整合到其放射科平台後，診所可以將影像解讀時間縮短 49%，提高病患接診能力，並在不影響診斷準確性的前提下，更有效地應對不斷成長的病患數量。

同時，標靶治療伴隨診斷的興起正推動著快速次世代定序(NGS) 在進行性甲狀腺惡性腫瘤診斷中的應用。隨著針對 RET 和 BRAF 等特定突變的新療法逐漸成為標準治療方案，迫切需要快速、全面的基因組分析，以便在確診後立即確定治療方案。這一趨勢正超越簡單的結節分類，將重點轉向檢測進行性癌症中可治療的突變，從而最佳化治療策略。 2025 年 8 月《CAP TODAY》雜誌發表了一篇題為「FDA核准的新型快速 NGS 解決方案上市」的報告，重點介紹了新核准的Oncomine Dx Express 檢測可在短短 24 小時內提供組織檢體的伴隨診斷結果。這種快速結果交付將使高風險甲狀腺癌患者能夠及時獲得個人化治療方案，從而加強醫療保健領域的協調。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球甲狀腺癌診斷市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（乳頭狀癌、濾泡狀癌、其他）
    • 透過檢查方法（血液檢查、影像診斷、切片檢查、其他）
    • 透過申請（醫院檢查室、癌症診斷中心、研究所等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美甲狀腺癌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲甲狀腺癌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區甲狀腺癌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲甲狀腺癌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲甲狀腺癌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球甲狀腺癌診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • F Hoffmann-La Roche AG
  • Abbott Laboratories Inc
  • Thermo Fisher Scientific Inc
  • General Electric Co
  • Siemens Healthcare GmbH
  • Bio-Rad Laboratories Inc
  • Toshiba Corporation
  • Koninklijke Philips NV
  • Agilent Technologies Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19980

The Global Thyroid Cancer Diagnostics Market is projected to expand from a valuation of USD 2.73 Billion in 2025 to USD 3.52 Billion by 2031, registering a compound annual growth rate of 4.33%. This sector encompasses a diverse range of clinical evaluations, such as high-resolution imaging, fine needle aspiration biopsy, and molecular genomic testing, all designed to identify and characterize thyroid malignancies. The market is primarily driven by the increasing global prevalence of endocrine disorders and a strong push for early disease detection to enhance therapeutic results. This rising disease burden requires rigorous screening protocols, which directly stimulates the adoption of specialized diagnostic technologies. Data from the American Cancer Society indicates that approximately 44,020 new cases of thyroid cancer were diagnosed in the United States in 2025, highlighting the urgent need for precise diagnostic instruments to effectively handle the substantial patient volume.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.73 Billion
Market Size 2031USD 3.52 Billion
CAGR 2026-20314.33%
Fastest Growing SegmentPapillary Carcinoma
Largest MarketNorth America

Despite this growth trajectory, the market faces a significant obstacle concerning the overdiagnosis of indolent thyroid nodules, a practice that frequently results in unnecessary surgeries and overtreatment. In response, regulatory authorities have revised screening guidelines to recommend more conservative management for small, low-risk nodules. These changes in clinical practice create uncertainty regarding reimbursement and decrease the number of diagnostic procedures conducted for minor cases, which subsequently hinders broader market expansion.

Market Driver

The escalating global incidence of thyroid cancer serves as a major driver for the diagnostics market, creating a necessity for robust screening protocols to accommodate increasing patient numbers. This surge is especially noticeable among younger populations, forcing healthcare systems to enhance their diagnostic capacities to facilitate earlier intervention. According to the World Health Organization's International Agency for Research on Cancer study titled 'Thyroid cancer in adolescents and young adults' from November 2025, there were over 237,000 new cases globally within this demographic in 2022. This increasing burden is also reflected in national statistics; for example, Cancer Research UK reported in September 2025 that approximately 4,000 new thyroid cancer cases are diagnosed annually in the region, emphasizing the ongoing requirement for effective detection methods across various populations.

In parallel, the rising integration of molecular diagnostics and genomic profiling is revolutionizing clinical workflows by resolving the difficulty of managing indeterminate thyroid nodules. Advanced genomic classifiers enable physicians to differentiate between benign and malignant nodules with improved precision, thereby lowering the rate of unnecessary diagnostic surgeries and ensuring better resource utilization. This movement toward precision medicine is demonstrated by the significant adoption of specialized testing products. In its 'Fourth Quarter and Full Year 2024 Financial Results' released in February 2025, Veracyte announced that its Afirma genomic test volume increased by 12% to exceed 60,000 tests for the full year 2024. Such strong adoption figures suggest that molecular testing is quickly becoming a standard of care, boosting market revenue through the use of higher-value diagnostic procedures.

Market Challenge

The principal obstacle restricting the thyroid cancer diagnostics market is the clinical shift aimed at mitigating the overdiagnosis of indolent thyroid nodules. Although the detection of minute, low-risk nodules historically triggered aggressive diagnostic evaluations, current practice standards increasingly prioritize active surveillance instead of immediate fine needle aspiration biopsy or molecular testing for small lesions. This move toward conservative management directly lowers the frequency of diagnostic interventions, thereby reducing the total volume of tests conducted and constraining revenue streams for diagnostic providers.

This decline in procedural volume creates a challenging landscape for market growth, as healthcare systems implement stricter reimbursement criteria to eliminate unnecessary expenses related to low-risk cases. According to estimates from the Canadian Cancer Society, approximately 6,900 individuals in Canada will be diagnosed with thyroid cancer in 2025. Although this incidence rate adds to the potential patient pool, the growing selectivity in clinical guidelines implies that a smaller proportion of patients with thyroid nodules will receive comprehensive diagnostic profiling. As a result, companies encounter limited utilization of premium diagnostic tools, since providers are restricting these advanced modalities to high-risk malignancies rather than using them for the routine screening of minor nodules.

Market Trends

The incorporation of Artificial Intelligence and Machine Learning into imaging is fundamentally transforming thyroid cancer detection by improving ultrasound accuracy and optimizing clinical operations. AI algorithms are increasingly being utilized to assess sonographic characteristics, assisting clinicians in distinguishing between benign and malignant nodules with greater precision than traditional visual analysis provides. This technological progress addresses the inconsistency in operator performance and notably boosts practice efficiency. For instance, RamSoft's September 2025 press release, 'RamSoft Partners with Koios Medical,' noted that integrating Koios DS AI software into radiology platforms allows clinics to reduce interpretation time by 49% while enhancing patient throughput, enabling providers to handle growing patient volumes more effectively without sacrificing diagnostic confidence.

At the same time, the rise of Companion Diagnostics for Targeted Therapies is fueling the growth of rapid next-generation sequencing (NGS) applications for advanced thyroid malignancies. As new therapies that target specific mutations such as RET and BRAF become standard practice, there is an urgent requirement for rapid and extensive genomic profiling to inform treatment choices immediately following diagnosis. This trend extends beyond basic nodule classification to focus on detecting actionable alterations in aggressive cancers to refine therapeutic strategies. A report in CAP TODAY from August 2025, titled 'Introduction of a new FDA approved rapid NGS solution,' highlights that the recently approved Oncomine Dx Express Test can provide companion diagnostic results from tissue samples within just 24 hours. This faster turnaround ensures that patients with high-risk thyroid cancer receive personalized treatment plans without substantial delays, thereby enhancing overall care coordination.

Key Market Players

  • F Hoffmann-La Roche AG
  • Abbott Laboratories Inc
  • Thermo Fisher Scientific Inc
  • General Electric Co
  • Siemens Healthcare GmbH
  • Bio-Rad Laboratories Inc
  • Toshiba Corporation
  • Koninklijke Philips NV
  • Agilent Technologies Inc

Report Scope

In this report, the Global Thyroid Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Thyroid Cancer Diagnostics Market, By Type

  • Papillary Carcinoma
  • Follicular Carcinoma
  • Others

Thyroid Cancer Diagnostics Market, By Technique

  • Blood Test
  • Imaging
  • Biopsy
  • Others

Thyroid Cancer Diagnostics Market, By End-use

  • Hospital Laboratories
  • Cancer Diagnostic Centers
  • Research Institutes
  • Others

Thyroid Cancer Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Thyroid Cancer Diagnostics Market.

Available Customizations:

Global Thyroid Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Thyroid Cancer Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Papillary Carcinoma, Follicular Carcinoma, Others)
    • 5.2.2. By Technique (Blood Test, Imaging, Biopsy, Others)
    • 5.2.3. By End-use (Hospital Laboratories, Cancer Diagnostic Centers, Research Institutes, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Thyroid Cancer Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Technique
    • 6.2.3. By End-use
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Thyroid Cancer Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Technique
        • 6.3.1.2.3. By End-use
    • 6.3.2. Canada Thyroid Cancer Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Technique
        • 6.3.2.2.3. By End-use
    • 6.3.3. Mexico Thyroid Cancer Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Technique
        • 6.3.3.2.3. By End-use

7. Europe Thyroid Cancer Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Technique
    • 7.2.3. By End-use
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Thyroid Cancer Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Technique
        • 7.3.1.2.3. By End-use
    • 7.3.2. France Thyroid Cancer Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Technique
        • 7.3.2.2.3. By End-use
    • 7.3.3. United Kingdom Thyroid Cancer Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Technique
        • 7.3.3.2.3. By End-use
    • 7.3.4. Italy Thyroid Cancer Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Technique
        • 7.3.4.2.3. By End-use
    • 7.3.5. Spain Thyroid Cancer Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Technique
        • 7.3.5.2.3. By End-use

8. Asia Pacific Thyroid Cancer Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Technique
    • 8.2.3. By End-use
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Thyroid Cancer Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Technique
        • 8.3.1.2.3. By End-use
    • 8.3.2. India Thyroid Cancer Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Technique
        • 8.3.2.2.3. By End-use
    • 8.3.3. Japan Thyroid Cancer Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Technique
        • 8.3.3.2.3. By End-use
    • 8.3.4. South Korea Thyroid Cancer Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Technique
        • 8.3.4.2.3. By End-use
    • 8.3.5. Australia Thyroid Cancer Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Technique
        • 8.3.5.2.3. By End-use

9. Middle East & Africa Thyroid Cancer Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Technique
    • 9.2.3. By End-use
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Thyroid Cancer Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Technique
        • 9.3.1.2.3. By End-use
    • 9.3.2. UAE Thyroid Cancer Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Technique
        • 9.3.2.2.3. By End-use
    • 9.3.3. South Africa Thyroid Cancer Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Technique
        • 9.3.3.2.3. By End-use

10. South America Thyroid Cancer Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Technique
    • 10.2.3. By End-use
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Thyroid Cancer Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Technique
        • 10.3.1.2.3. By End-use
    • 10.3.2. Colombia Thyroid Cancer Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Technique
        • 10.3.2.2.3. By End-use
    • 10.3.3. Argentina Thyroid Cancer Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Technique
        • 10.3.3.2.3. By End-use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Thyroid Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F Hoffmann-La Roche AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Abbott Laboratories Inc
  • 15.3. Thermo Fisher Scientific Inc
  • 15.4. General Electric Co
  • 15.5. Siemens Healthcare GmbH
  • 15.6. Bio-Rad Laboratories Inc
  • 15.7. Toshiba Corporation
  • 15.8. Koninklijke Philips NV
  • 15.9. Agilent Technologies Inc

16. Strategic Recommendations

17. About Us & Disclaimer